Intellia Therapeutics Stock Investor Sentiment
| NTLA Stock | USD 15.21 0.48 3.26% |
About 64% of all Intellia Therapeutics' investors are looking to take a long position. The analysis of the overall investor sentiment regarding Intellia Therapeutics suggests that some traders are interested. The current market sentiment, together with Intellia Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Intellia Therapeutics stock news signals to limit their universe of possible portfolio assets.
Panic Vs Confidence
64
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Intellia Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Intellia Therapeutics.
News SentimentBullish | Hype SentimentBullish | Insider SentimentDisposing |
Intellia Historical Sentiment
Although Intellia Therapeutics' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Intellia, such as negative comments on social media and news outlets, may cause fear in the market and push Intellia Therapeutics' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Intellia.
Intellia |
Intellia Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Intellia Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Intellia Therapeutics Historical Investor Sentiment
Investor biases related to Intellia Therapeutics' public news can be used to forecast risks associated with an investment in Intellia. The trend in average sentiment can be used to explain how an investor holding Intellia can time the market purely based on public headlines and social activities around Intellia Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Intellia Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Intellia Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Intellia Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on Intellia Therapeutics.
Far too much social signal, news, headlines, and media speculation about Intellia Therapeutics that are available to investors today. That information is available publicly through Intellia media outlets and privately through word of mouth or via Intellia internal channels. However, regardless of the origin, that massive amount of Intellia data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Intellia Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Intellia Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Intellia Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Intellia Therapeutics alpha.
Intellia Therapeutics Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Intellia Therapeutics, Inc. Receives Consensus Recommendation of Moderate Buy from Analysts - MarketBeat | 09/27/2024 |
2 | Disposition of 2012 shares by Dube Michael P of Intellia Therapeutics at 19.01 subject to Rule 16b-3 | 10/02/2024 |
3 | Is Intellia Therapeutics, Inc. the Most Promising Biotech Stock According to Hedge Funds | 10/16/2024 |
4 | Intellia Therapeutics Announces Two Upcoming Investor Eventsin November 2024 | 10/31/2024 |
5 | Intellia Therapeutics Inc Q3 2024 Earnings Call Highlights Financial Stability and ... | 11/08/2024 |
6 | Intellia Therapeutics SWOT analysis gene editing stocks progress and potential | 11/12/2024 |
7 | Cathie Wood says her volatile ARK Innovation fund shouldnt be a huge slice of any portfolio | 11/15/2024 |
8 | CF Foundation Invests Up to 15 million in ReCode Therapeutics to Develop a Gene Editing Therapy | 11/18/2024 |
9 | Intellia Therapeutics price target lowered to 70 from 80 at Wells Fargo | 11/19/2024 |
10 | Down 33 percent in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock | 11/22/2024 |
11 | Intellia Therapeutics SWOT analysis gene editing firms stock faces pivotal trials | 11/25/2024 |
Complementary Tools for Intellia Stock analysis
When running Intellia Therapeutics' price analysis, check to measure Intellia Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intellia Therapeutics is operating at the current time. Most of Intellia Therapeutics' value examination focuses on studying past and present price action to predict the probability of Intellia Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intellia Therapeutics' price. Additionally, you may evaluate how the addition of Intellia Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Stocks Directory Find actively traded stocks across global markets | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |